This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
With so many choices out there, it's time to narrow the field.
*FDA approved for 2 to 3 times weekly dosing.
Once you've found a therapy with a twice-weekly dosing option* and ZERO bleeds (median AsBR†), other things can be taken into consideration.
Of these 3 FVIII products, only AFSTYLA is covered by 3 of the largest national plans (pharmacy benefit managers).
With more than 30 years of experience in bleeding disorders, CSL Behring remains committed to developing innovative therapies.
ZERO inhibitors were observed in 258 previously treated children, adolescents, and adults in clinical trials.
*FDA approved for dosing 2 to 3 times a week.
†AsBR=annualized spontaneous bleeding rate.
Download a Doctor Discussion Guide and get your questions answered at your next appointment
When you're ready to give AFSTYLA a try, simply print this form and give it to your doctor to request your free 30-day trial. All insured patients are eligible, including those covered by Medicare and Medicaid.
Be sure to sign up for the latest information on hemophilia A and AFSTYLA—and request your free AFSTYLA Discovery Kit!
If you need assistance, speak with a My Source™ Care Coordinator at 1-800-676-4266 Monday through Friday, 8 am to 8 pm ET.
